• There are no suggestions because the search field is empty.

Why start building IVDR-compliant Technical Documentation now? 

Author Avatar
Kirsten Van Garsse, Director AR Services and Manager IVD - RA and Pieter Bogaert, Senior Consultant IVD - RA
Clinical
Regulatory Affairs
In Vitro Diagnostics
Even with the European Commission's proposal for extending the transitional period for IVDs, manufacturers should start building compliant Technical Documentation now. This article highlights the importance of proactive action despite the proposed delay.
Why start building IVDR-compliant Technical Documentation now? | QbD Group
3:02

 
 

 

With the European Commission’s proposal for extending the transitional period for In Vitro Diagnostic Devices (IVDs), many manufacturers of legacy devices may feel they have gained breathing room. Amidst these discussions, the question may arise: why should manufacturers already begin building their IVDR-compliant Technical Documentation now? Let’s delve into the critical reasons why proactive action is imperative despite the proposed extensions. 

 

The proposal and its implications

The proposal for extending the transitional period is just that—a proposal. While the exact text and timings are yet to be finalized, it’s clear that manufacturers with legacy devices will be granted additional time to complete their Technical Documentation under the IVDR. However, it’s essential to view the proposed deadlines for lodging applications for conformity assessment as the ultimate deadlines for having Technical Documentation ready for all legacy devices. 

 

Realistic timelines and considerations

The timelines for IVDR compliance are not as forgiving as they may seem. The average time from contacting a notified body to achieving IVDR certification can take up to 18 – 24 months. Moreover, the complexity of Technical Documentation preparation and the potential for deficiencies in initial submissions mean that starting the process sooner rather than later is paramount. 

 

Class D and Class C urgency

For manufacturers of Class D and Class C products, the urgency to commence Technical Documentation preparation cannot be overstated. These products undergo the highest scrutiny and often require extensive clinical evidence and performance studies. Companion diagnostics, in particular, face longer review times due to the additional involvement of competent authorities of medicinal products designated by the Member States or the European Medicines Agency (EMA), making early action imperative. 

 

Strategy and planning for Class B products

Even for Class B products, strategic planning and gap assessments are critical. Mapping out submission strategies, conducting pilot submissions, and factoring in minimum review times by notified bodies are essential steps in ensuring timely IVDR compliance. Waiting until the last minute could result in resource shortages and regulatory bottlenecks, both at the side of the manufacturer and the notified body. 

 

Conclusion: Take action now

In essence, the proposed extension of the transitional period should not be misconstrued as a delay. Rather, it serves as an opportunity for manufacturers to expedite their IVDR compliance efforts. By initiating gap assessments, creating remediation plans, and beginning the process of Technical Documentation preparation sooner rather than later, manufacturers can navigate the complexities of IVDR compliance more effectively. The time to act is now—to secure regulatory compliance and, maintain competitiveness in the evolving landscape of the European IVD regulation. 

 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Blog

What Makes Usability Testing Crucial for Near-Patient and Self-Testing Devices under IVDR?

It shouldn’t be a surprise that today, “Near-Patient Testing (NPT)” and...
preview_image
Blog

When does Annex XIV apply in Performance Studies, and what key documentation is needed for compliance?

In the European regulatory landscape, conducting performance studies for in...
preview_image
Blog

How to define your Clinical Performance Strategy?

1. Start with a clear intended purpose A strong clinical...
preview_image
Blog

The Holy Grail: Achieving Inspection Readiness

In a previous blog post, we talked about the various activities...